Daxor (NASDAQ:DXR – Free Report) had its price objective upped by Ascendiant Capital Markets from $24.75 to $25.00 in a research report report published on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.
Daxor Stock Down 2.6 %
DXR stock opened at $7.97 on Monday. The company has a fifty day moving average price of $7.79 and a two-hundred day moving average price of $8.48. Daxor has a one year low of $6.55 and a one year high of $10.00.
Insiders Place Their Bets
In related news, CEO Michael Richard Feldschuh acquired 3,360 shares of Daxor stock in a transaction on Monday, March 10th. The stock was purchased at an average cost of $7.68 per share, with a total value of $25,804.80. Following the completion of the transaction, the chief executive officer now directly owns 210,852 shares in the company, valued at $1,619,343.36. This trade represents a 1.62 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 59.00% of the company’s stock.
Institutional Investors Weigh In On Daxor
Daxor Company Profile
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Featured Stories
- Five stocks we like better than Daxor
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Can TikTok Stock Picks Really Make You Rich?
- 3 Dividend Kings To Consider
- The “Quality” Rotation: Back to Basics Investing
- Investing in Commodities: What Are They? How to Invest in Them
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.